In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3777-3781

  Osborne, Colin S ^a   Neckermann, Georg ^a,b   Fischer, Evelin ^a,c   Pecanka, Robert ^a   Yu, Donghui ^a   Manni, Kari ^a   Goldovitz, Julie ^a   Amaral, Kerri ^a   Dzink Fox, JoAnn ^a   Ryder, Neil S ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Nabriva Therapeutics Inc   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; LINEZOLID; MOXIFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PENICILLIN G; PENICILLIN V; PEPTIDE DEFORMYLASE INHIBITOR; TELITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; IN VIVO STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SOFT TISSUE INFECTION;

ACETAMIDES; AMIDOHYDROLASES; ANIMALS; ANTI-INFECTIVE AGENTS; FEMALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OXAZOLIDINONES; PEPTIDES; PNEUMONIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THIGH;

EID: 70349089259     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00026-09     Document Type: Article

References (24)

1. Azoulay-Dupuis, E., J. Mohler, and J. P. Bédos. 2004. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:80-85.
2. Bogdanovich, T., K. A. Smith, C. Clark, G. A. Pankuch, G. Lin, P. McGhee, B. Dewasse, and P. C. Appelbaum. 2006. Activity of LBM415 compared to those of 11 other agents against Haemophilus species. Antimicrob. Agents Chemother. 50:2323-2329.
3. Brown, S. D., and D. J. Farrell. 2004. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J. Antimicrob. Chemother. 54:i23-i29.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard-7th ed. CLSI document M7-A7. CLSI, Wayne, PA.
5. Credito, K., G. Lin, L. M. Ednie, and P. C. Appelbaum. 2004. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4033-4036.
6. Ednie, L. M., G. Pankuch, and P. C. Appelbaum. 2004. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4027-4032.
7. Fonseca-Aten, M., C. M. Salvatore, A. Mejías, A. M. Ríos, S. Chávez-Bueno, K. Katz, A. M. Gómez, G. H. McCracken Juniorperiod, and R. D. Hardy. 2005. Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob. Agents Chemother. 49:4128-4136.
8. Frimodt-Møller, N., J. D. Knudesen, and F. Espersen. 1999. The mouse peritonitis/sepsis model, p. 127-136. In O. Zak and M. A. Sande (ed.), Handbook of animal models of infection, 1st ed. Academic Press, San Diego, CA.
9. Fritsche, T. R., H. S. Sader, R. Cleeland, and R. N. Jones. 2005. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 49:1468-1476.
10. Giglione, C., M. Pierre, and T. Meinnel. 2000. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol. 36:1197-1205.
11. Jain, R., D. Chen, R. J. White, D. V. Patel, and Z. Yuan. 2005. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 12:1607-1621.
12. Jenkins, S. G., S. D. Brown, and D. J. Farrell. 2008. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US years 1-4. Ann. Clin. Microbiol. Antimicrob. 7:1.
13. Jones, R. N., T. R. Fritsche, and H. S. Sader. 2004. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49:63-65.
14. Jones, R. N., G. J. Moet, H. S. Sader, and T. R. Fritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone- resistant or streptogramin-resistant gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.
15. Khare, M., and D. Keady. 2003. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Exp. Opin. Pharmacother. 4:165-177.
16. Leeds, J. A., and C. R. Dean. 2006. Peptide deformylase as an antibacterial target: a critical assessment. Curr. Opin. Pharmacol. 6:445-452.
17. McCormick, A. W., C. G. Whitney, M. M. Farley, R. Lynfield, L. H. Harrison, N. M. Bennett, W. Schaffner, A. Reingold, J. Hadler, P. Cieslak, M. H. Samore, and M. Lipsitch. 2003. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat. Med. 9:424-430.
18. Nguyen, K. T., X. Hu, C. Colton, R. Chakrabarti, M. X. Zhu, and D. Pei. 2003. Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry 42:9952-9958. (Pubitemid 37012871)
19. Noskin, G. A., R. J. Rubin, J. J. Schentag, J. Kluytmans, E. C. Hedblom, C. Jacobson, M. Smulders, E. Gemmen, and M. Bharmal. 2007. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin. Infect. Dis. 45:1132-1140.
20. Rice, L. B. 2006. Unmet medical needs in antibacterial therapy. Biochem. Pharmacol. 71:991-995.
21. Rice, L. B. 2006. Antimicrobial resistance in gram-positive bacteria. Am. J. Med. 119:S11-S19.
22. Schrag S. J., L. McGee, C. G. Whitney, B. Beall, A. S. Craig, M. E. Choate, J. H. Jorgensen, R. R. Facklam, K. P. Klugman, et al. 2004. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob. Agents Chemother. 48:3016-3023.
23. Watters, A. A., R. N. Jones, J. A. Leeds, G. Denys, H. S. Sader, and T. R. Fritsche. 2006. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J. Antimicrob. Chemother. 57:914-923.
24. Wilson, R., and C. Rayner. 1994. Animal models of respiratory infection. J. Antimicrob. Chemother. 33:381-386.